24/7 Market News Snapshot 02 October, 2025 – Taysha Gene Therapies, Inc. Common Stock (NASDAQ:TSHA)

October 2, 2025

DENVER, Colo., 02 October, 2025 (www.247marketnews.com) – (NASDAQ:TSHA) are discussed in this article.
Taysha Gene Therapies, Inc. is experiencing a remarkable surge in pre-market trading, with shares priced at $4.329, reflecting a significant 36.13% increase from the previous day’s close of $3.180. This impressive rise is supported by a robust trading volume of 4.30 million shares, indicating a heightened level of investor interest and confidence in the company’s future prospects. Technical indicators suggest a breakout, with sustained buying pressure expected to drive prices higher as market sentiment becomes increasingly favorable toward Taysha.

The surge in market activity coincides with the noteworthy achievement of receiving Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for TSHA-102, Taysha’s innovative gene therapy aimed at treating Rett syndrome. This designation highlights the FDA’s recognition of the compelling clinical evidence presented from the REVEAL Phase 1/2 trials, where TSHA-102 exhibited a remarkable 100% response rate in patients meeting predefined developmental milestones. This stands in stark contrast to the less than 6.7% response expected based on historical data.

The FDA’s alignment with Taysha regarding the pivotal trial protocol and statistical analysis plan marks a significant step forward, with patient enrollment anticipated to commence by the end of 2025. Ongoing results indicate a dose-dependent improvement across various outcome measures, further solidifying Taysha’s commitment to addressing the substantial unmet medical need for the approximately 10,000 individuals in the U.S. affected by Rett syndrome.

“Receiving Breakthrough Therapy designation from the FDA is a testament to our commitment to developing transformative therapies for patients with Rett syndrome,” remarked Rumana Haque-Ahmed, Chief Regulatory Officer of Taysha. With TSHA-102 leading the charge, Taysha Gene Therapies is strategically positioned to transform the therapeutic landscape for severe genetic disorders.

Related news for (TSHA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.